Takeda Pharmaceutical is bolstering its pipeline in a big way, committing $1.2 billion for rights to two late-stage Innovent Biologics cancer drugs and securing an exclusive option to license an early ...

This year’s J.P. Morgan Healthcare Conference in San Francisco, which wrapped on Thursday, brought together healthcare leaders from across the globe to convene, discuss industry trends and give ...

On Wednesday, 60 organizations representing providers and patients with cancer submitted a letter to Robert F. Kennedy Jr., secretary of Health and Human Services, urging him to protect the U.S.

Many of Eli Lilly’s acquisitions this year double down in areas where the company is already a player, such as cancer and inflammatory disorders. Lilly is now broadening its scope to a new area, ...

Many people view precision medicine as healthcare’s next frontier. The field promises a future where treatments are tailored to each patient’s unique genes, biology and disease risk, with the goal of ...

Most disputes between pharmaceutical companies and generic drugmakers end in settlements. Five years of class-action litigation over a Takeda Pharmaceutical gastrointestinal drug culminated this week ...

Digital health funding is holding steady — venture capital is flowing, IPOs are reappearing, and megarounds are back in force. Startups in this space have raised $9.9 billion throughout the first ...

Three health systems are suing CVS Health, alleging the company and its pharmacy subsidiaries diverted roughly $250 million in savings from the 340B Drug Pricing Program. The 340B program was ...

Employer advocates said Cost Plus Wellness could help spur more direct contracting and transparency in healthcare, though ...

When cell therapy first reached patients as targeted treatment for the toughest cases of blood cancer, scientists thought this novel therapeutic modality might also find use in autoimmune conditions.